These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

847 related articles for article (PubMed ID: 2361171)

  • 1. Regulation of the synthesis and metabolism of striatal dopamine after disruption of nerve conduction in the medial forebrain bundle.
    Commissiong JW; Slimovitch C; Toffano G
    Br J Pharmacol; 1990 Apr; 99(4):741-9. PubMed ID: 2361171
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Regulatory aspects of nigrostriatal dopaminergic neurons.
    Miu P; Karoum F; Toffano G; Commissiong JW
    Exp Brain Res; 1992; 91(3):489-95. PubMed ID: 1483521
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Behavioral activation in rats increases striatal dopamine metabolism measured by dialysis perfusion.
    Salamone JD; Keller RW; Zigmond MJ; Stricker EM
    Brain Res; 1989 May; 487(2):215-24. PubMed ID: 2786443
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dopamine metabolism in the striatum of hemiparkinsonian model rats with dopaminergic grafts.
    Hashitani T; Mizukawa K; Kumazaki M; Nishino H
    Neurosci Res; 1998 Jan; 30(1):43-52. PubMed ID: 9572579
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The central aromatic amino acid DOPA decarboxylase inhibitor, NSD-1015, does not inhibit L-DOPA-induced circling in unilateral 6-OHDA-lesioned-rats.
    Treseder SA; Rose S; Jenner P
    Eur J Neurosci; 2001 Jan; 13(1):162-70. PubMed ID: 11135014
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activation of striatal dopaminergic grafts by haloperidol.
    Herman JP; Choulli K; Le Moal M
    Brain Res Bull; 1985 Dec; 15(6):543-6. PubMed ID: 3936594
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Trans-striatal dialysis coupled to reverse phase high performance liquid chromatography with electrochemical detection: a new method for the study of the in vivo release of endogenous dopamine and metabolites.
    Imperato A; Di Chiara G
    J Neurosci; 1984 Apr; 4(4):966-77. PubMed ID: 6716134
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chronic intranigral administration of brain-derived neurotrophic factor produces striatal dopaminergic hypofunction in unlesioned adult rats and fails to attenuate the decline of striatal dopaminergic function following medial forebrain bundle transection.
    Lapchak PA; Beck KD; Araujo DM; Irwin I; Langston JW; Hefti F
    Neuroscience; 1993 Apr; 53(3):639-50. PubMed ID: 8098137
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biotransformation of locally applied L-dopa in the corpus striatum of the hemi-parkinsonian rat studied with microdialysis.
    Sarre S; De Klippel N; Herregodts P; Ebinger G; Michotte Y
    Naunyn Schmiedebergs Arch Pharmacol; 1994 Jul; 350(1):15-21. PubMed ID: 7935849
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Partial lesions of the nigrostriatal pathway in the rat. Acceleration of transmitter synthesis and release of surviving dopaminergic neurones by drugs.
    Hefti F; Enz A; Melamed E
    Neuropharmacology; 1985 Jan; 24(1):19-23. PubMed ID: 2858830
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Time course of adaptations in dopamine biosynthesis, metabolism, and release following nigrostriatal lesions: implications for behavioral recovery from brain injury.
    Altar CA; Marien MR; Marshall JF
    J Neurochem; 1987 Feb; 48(2):390-9. PubMed ID: 3794713
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevention by (+/-)-8-hydroxy-2-(di-n-propylamino)tetralin of both catalepsy and the rises in rat striatal dopamine metabolism caused by haloperidol.
    Andersen HL; Kilpatrick IC
    Br J Pharmacol; 1996 May; 118(2):421-7. PubMed ID: 8735647
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of phencyclidine on dopamine synthesis and metabolic in rat striatum.
    Doherty JD; Simonovic M; So R; Meltzer HY
    Eur J Pharmacol; 1980 Jul; 65(2-3):139-49. PubMed ID: 7398783
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Age influences abnormalities in striatal dopamine metabolism during and after transient forebrain ischemia.
    Ding A; Németh G; Hoyer S
    J Neural Transm Park Dis Dement Sect; 1992; 4(3):213-25. PubMed ID: 1627255
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of probenecid on endogenous and exogenous 3,4-dihydroxyphenylacetic acid and homovanillic acid in the rat brain.
    Broch OJ
    Eur J Pharmacol; 1976 Sep; 39(1):33-40. PubMed ID: 964303
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term decreases in striatal dopamine, 3,4-dihydroxyphenylacetic acid, and homovanillic acid after a single injection of amphetamine in iprindole-treated rats: time course and time-dependent interactions with amfonelic acid.
    Steranka LR
    Brain Res; 1982 Feb; 234(1):123-36. PubMed ID: 7059818
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Striatal L-dopa metabolism studied in vivo in rats with nigrostriatal lesions.
    Brannan T; Bhardwaj A; Martinez-Tica J; Weinberger J; Yahr M
    J Neural Transm Park Dis Dement Sect; 1990; 2(1):15-22. PubMed ID: 2113388
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modification of the striatal dopaminergic neuron system by carbon monoxide exposure in free-moving rats, as determined by in vivo brain microdialysis.
    Hara S; Mukai T; Kurosaki K; Kuriiwa F; Endo T
    Arch Toxicol; 2002 Oct; 76(10):596-605. PubMed ID: 12373456
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dopaminergic mediation of beta-endorphin-induced catalepsy.
    Van Loon GR; Kim C
    Res Commun Chem Pathol Pharmacol; 1978 Jul; 21(1):37-44. PubMed ID: 567367
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of neuroleptic drugs on striatal dopamine release and metabolism in the awake rat studied by intracerebral dialysis.
    Zetterström T; Sharp T; Ungerstedt U
    Eur J Pharmacol; 1984 Oct; 106(1):27-37. PubMed ID: 6085051
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 43.